Oncotelic Therapeutics has reported that its lead drug candidate, OT-101, met the safety and efficacy goals of Phase II C001 clinical trial in individuals with severe Covid-19 who are admitted to the hospital.
An anti-TGF-β ribonucleic acid therapy, OT-101 demonstrated single-agent activity in individuals with relapsed/refractory cancer in various trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAs part of the immune evasion mechanisms, tumour cells and the SARS-CoV-2 virus produce TGF- β.
As a result, suppressing TGF- β using OT-101 could have an effect on both cancer and Covid-19.
As compared to standard antiviral therapies and vaccines, OT-101 potentially works against several respiratory viruses by acting on the host protein.
The randomised, placebo-controlled, double-blind, multicentre trial evaluated OT-101 in combination with the standard of care (SOC) as against placebo plus SOC in a total of 32 subjects.
SOC comprises dexamethasone, a drug claimed to boost outcomes in individuals with severe Covid-19.
Findings showed that OT-101 met the safety goals of the trial, indicating that the TGF-β inhibitor therapy was safe to use in people with Covid-19, including those with severe/critical disease.
Furthermore, the mortality was 4.5% in the subjects treated with OT-101 compared to 20% in the placebo arm on day seven, meeting the efficacy signals.
On day seven, 89% of the subjects who received OT-101 had more than 96% reduction in viral load as against 67% in the placebo group.
Overall survival rose by three times for critical patients treated with OT-101, reported at 14 days for OT-101 versus four for those who received placebo.
Oncotelic CEO and chairman Dr Vuong Trieu said: “It is gratifying that the TGF-β concept that we put forward has now been validated.
“The data form the basis for further development of OT-101 as a viable treatment for severe respiratory viral infections, including flu and Covid-19.”
In August 2019, Mateon, which formed due to a reverse merger with Oncotelic, took over the computer and artificial intelligence company PointR Data.
